OPTIBIOME® BS50 (Bacillus subtilis Spore Probiotic — BIO-CAT)

Bacillus subtilis
Evidence Level
Limited
2 Clinical Trials
3 Documented Benefits
2/5 Evidence Score

OPTIBIOME BS50 is BIO-CAT's spore-forming probiotic strain Bacillus subtilis BS50 (also called BS8-74, deposited as ATCC PTA-127287), isolated from Montana soil and produced by BIO-CAT Microbials in Shakopee, Minnesota. It is a different strain from DE111, CU1 and BIO-CAT's MB40, and results do not carry over between strains. In a placebo-controlled trial in 76 healthy adults with gas-related symptoms, 2 billion CFU a day for 6 weeks raised the share who improved on a combined bloating, burping and flatulence score, the registered main outcome. Of the single symptoms only burping differed from placebo; bloating did not reach significance. BIO-CAT funded the trial and took part in its design and writing. A maker-run genome and cell culture screen found no known Bacillus toxin genes.

Studied Dose One capsule of 2 billion CFU a day with the largest meal of the day for 6 weeks (the one published human trial).
Active Compound Spores of Bacillus subtilis strain BS50 (also called BS8-74, deposited as ATCC PTA-127287), isolated from soil in Gallatin County, Montana, and produced by BIO-CAT Microbials in Shakopee, Minnesota.

Benefits

Gas-related digestive symptoms in healthy adults

In 76 healthy adults with gas-related symptoms, 2 billion CFU of BS50 a day for 6 weeks raised the share who improved on a combined bloating, burping and flatulence score, the registered main outcome, to 47.4 versus 22.2 percent on placebo. BIO-CAT funded the trial and took part in its design and writing.

Burping, bloating and other single symptoms

Of the single symptoms in the same trial, only burping improved more than on placebo (44.7 versus 22.2 percent, p = .041). Bloating did not reach significance (31.6 versus 13.9 percent, p = .071), and nausea, cramping, stomach rumbling, reflux, bowel habits and stool consistency did not differ.

Blood tests, sleep and other measured outcomes

Over the 6 week trial, blood chemistry, blood counts, lipids, gut permeability markers and inflammation markers showed no clinically meaningful changes, and sleep quality did not change. Respiratory infections were planned as an outcome, but too few occurred to compare the groups.

Mechanism of action

1

Spore form

BS50 is taken as dormant spores. A review of Bacillus probiotics describes spores as heat stable and able to survive the stomach. Whether BS50 spores germinate in the human gut has not been measured; the trial authors point to a study of a different strain, DE111, whose spores germinated in the small intestine within 3 hours.

2

Enzymes and antimicrobial genes

The trial paper reports that BS50 cells secreted digestive enzymes in lab tests, and its authors propose that enzymes released in the gut could reduce fermentation and gas, while stating that the mechanism is unknown. The BS50 genome carries gene clusters for antimicrobial compounds such as fengycins, which the authors suggest may help balance gut bacteria; this was not tested in people.

Clinical trials

1
OPTIBIOME BS50 for gas-related digestive symptoms: 6 week placebo-controlled trial
PubMed

Randomized, double-blind, placebo-controlled parallel trial at one site (Biofortis Research, Addison, Illinois), July to November 2021; one capsule of 2 billion CFU BS50 or maltodextrin placebo daily with the largest meal for 6 weeks; registered NCT05004454 with bloating, flatulence and burping as the primary outcome; funded by BIO-CAT, whose employees were two of five authors; the funders took part in design, writing and the decision to publish, and BIO-CAT Microbials filed a related patent application (Garvey et al. 2022, Gut Microbes)

76 healthy adults aged 30 to 65 (38 per group, average age about 50) with a combined bloating, burping and flatulence score of 3 or more in the baseline week.

Primary outcome met: 47.4 percent on BS50 versus 22.2 percent on placebo improved on the combined bloating, burping and flatulence score (OR 3.2, 95% CI 1.1 to 8.7, p = .024). Burping alone improved more than on placebo (44.7 versus 22.2 percent, p = .041); bloating did not reach significance (31.6 versus 13.9 percent, p = .071), and other symptoms, bowel habits and stool consistency did not differ. Blood tests showed no clinically meaningful changes.

2
BS50 preclinical safety screen (genome and cell culture, not a human trial)
PubMed

Genome screening for toxin, virulence, secondary metabolite and antibiotic resistance genes, antibiotic MIC testing against eight antibiotics, and tests of BS50 cell lysates on cultured human Caco-2 cells; funded by BIO-CAT, whose employees were three of four authors and which took part in design, analysis and writing (Brutscher et al. 2022, Microorganisms)

No people: the BS50 genome, BS50 cells and cultured Caco-2 cells.

No known Bacillus toxin genes were found. BS50 was susceptible to seven of eight antibiotics and resistant to streptomycin, and no resistance gene sat within a complete mobile genetic element. BS50 lysates did not reduce Caco-2 cell viability or monolayer permeability. Lab data only; it does not measure long-term use in people.

Side effects and drug interactions

Common Potential side effects

In the 6 week trial, the only adverse event judged possibly related to the study product was reported by a participant in the placebo group, and blood chemistry, blood counts, blood pressure and body weight showed no adverse changes.
A maker-run genome and cell culture screen found no known Bacillus toxin genes; in lab tests BS50 was resistant to streptomycin, and no resistance gene sat within a complete mobile genetic element.
Published human data cover 6 weeks of daily use in healthy adults aged 30 to 65; longer use has not been studied.
The trial excluded pregnant women, and no BS50 study has included pregnant or breastfeeding women; ask a doctor before use.
As with other live probiotics, people who are severely ill or have a weakened immune system should ask a doctor before use.

Important Drug interactions

No drug interaction studies of BS50 have been published.
Antibiotics: in lab tests BS50 was susceptible to seven of eight antibiotics tested, so an antibiotic course may affect it; ask a pharmacist about spacing doses.
Immunosuppressants and chemotherapy: ask a doctor before taking any live probiotic.

Frequently asked questions about OPTIBIOME® BS50 (Bacillus subtilis Spore Probiotic — BIO-CAT)

What is OPTIBIOME BS50 used for?

It is a spore-forming probiotic sold for digestive comfort. In one maker-funded, placebo-controlled trial in 76 healthy adults with gas-related symptoms, 6 weeks raised the share who improved on a combined bloating, burping and flatulence score. Only burping improved on its own.

How is BS50 different from other Bacillus subtilis strains?

BS50 is its own strain (ATCC PTA-127287). DE111, CU1 and BIO-CAT's MB40 are different strains with their own trials, and results for one do not carry over to another.

What is the recommended dosage of OPTIBIOME BS50?

The trial used one capsule of 2 billion CFU a day with the largest meal of the day for 6 weeks. Follow the product label.

Is OPTIBIOME BS50 safe, and does it have side effects?

In the 6 week trial, the only adverse event judged possibly related to the study product occurred in the placebo group, and blood tests showed no adverse changes. Longer use, pregnancy and breastfeeding have not been studied. People who are severely ill or immunocompromised should ask a doctor before taking live probiotics.

What is OPTIBIOME BS50?

Optibiome BS50 is BIO-CAT's spore-forming probiotic strain Bacillus subtilis BS50 (also called BS8-74, deposited as ATCC PTA-127287), isolated from Montana soil and produced by BIO-CAT Microbials in Shakopee, Minnesota.

Does OPTIBIOME BS50 interact with any medications?

Possible interactions include: No drug interaction studies of BS50 have been published. Antibiotics: in lab tests BS50 was susceptible to seven of eight antibiotics tested, so an antibiotic course may affect it; ask a pharmacist about spacing doses. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for OPTIBIOME BS50?

NutraSmarts rates the evidence for OPTIBIOME BS50 as Limited (2 out of 5). It is backed by 2 study summaries and 6 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(6 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Garvey SM, Mah E, Blonquist TM, Kaden VN, Spears JL. The probiotic Bacillus subtilis BS50 decreases gastrointestinal symptoms in healthy adults: a randomized, double-blind, placebo-controlled trial. Gut Microbes. 2022;14(1):2122668. doi: 10.1080/19490976.2022.2122668.PubMedUsed to support: Randomized, double-blind, placebo-controlled parallel trial (NCT05004454) at one site in 76 healthy adults aged 30 to 65 with at least mild bloating, burping or flatulence. One capsule of 2 billion CFU BS50 with the largest meal for 6 weeks raised the share improving on the combined bloating, burping and flatulence score, the primary outcome, versus placebo (47.4 versus 22.2 percent, OR 3.2, 95% CI 1.1 to 8.7, p = .024). Burping alone also improved (44.7 versus 22.2 percent, p = .041); bloating did not reach significance (31.6 versus 13.9 percent, p = .071), and other symptoms, bowel habits, stool consistency, sleep, lipids, gut permeability and inflammation markers did not differ. Funded by BIO-CAT, whose employees were two of five authors; the funders took part in design, writing and the decision to publish, and BIO-CAT Microbials filed a related patent application. The full text names the strain as BS8-74, ATCC PTA-127287, and says pregnant women were excluded.
  2. Brutscher LM, Borgmeier C, Garvey SM, Spears JL. Preclinical Safety Assessment of Bacillus subtilis BS50 for Probiotic and Food Applications. Microorganisms. 2022;10(5):1038. doi: 10.3390/microorganisms10051038.PubMedUsed to support: Preclinical safety assessment of BS50 using genome screening, antibiotic MIC testing and human intestinal (Caco-2) cell culture, not a study in people. It found no known Bacillus toxin genes, susceptibility to seven of eight tested antibiotics with resistance to streptomycin, no antibiotic resistance genes flanked by complete mobile genetic elements, and no loss of Caco-2 viability or permeability. Funded by BIO-CAT, whose employees were three of four authors and which took part in design, analysis and writing. It does not measure any benefit, long-term use, oxygen tolerance or shelf stability.
  3. BIO-CAT Microbials, LLC (sponsor); ClinicalTrials.gov, US National Library of Medicine. A Randomized, Parallel, Double-blind, Placebo-Controlled Study to Investigate the Effect of a Bacillus Subtilis BS50 Spore Preparation on Gastrointestinal Symptoms in Healthy Adults. NCT05004454. ClinicalTrials.gov. 2026;Registry record; accessed 2026..SourceUsed to support: Not PubMed-indexed (trial registry record, read via the ClinicalTrials.gov API). Lists BIO-CAT Microbials as sponsor and Biofortis Clinical Research as collaborator, 76 enrolled from July 2021, abdominal bloating, flatulence and/or burping on the 8-item Gastrointestinal Tolerance Questionnaire over 6 weeks as the primary outcome, and bowel function, gut permeability, immune and lipid markers, respiratory infections and sleep as secondary outcomes.
  4. BIO-CAT, Inc. OPTIBIOME BS50® product page. BIO-CAT website. 2026;Manufacturer web page; accessed 2026..SourceUsed to support: Not PubMed-indexed (manufacturer web page, read online). Spells the brand OPTIBIOME BS50 and links the Garvey 2022 Gut Microbes trial and the Microorganisms preclinical safety study as the product's clinical and safety papers. Cited only to tie the brand name to the BS50 studies.
  5. Cutting SM. Bacillus probiotics. Food Microbiol. 2011;28(2):214-20. doi: 10.1016/j.fm.2010.03.007.PubMedUsed to support: Review of Bacillus species used as probiotics in feeds, supplements and medicines, their safety and mode of action. States that spore formers are attractive as food additives because of their heat stability and ability to survive the gastric barrier. Not specific to BS50.
  6. Colom J, Freitas D, Simon A, Brodkorb A, Buckley M, Deaton J, Winger AM. Presence and Germination of the Probiotic Bacillus subtilis DE111(®) in the Human Small Intestinal Tract: A Randomized, Crossover, Double-Blind, and Placebo-Controlled Study. Front Microbiol. 2021;12:715863. doi: 10.3389/fmicb.2021.715863.PubMedUsed to support: Other strain (B. subtilis DE111 from Deerland), not BS50. In 11 people with an ileostomy, swallowed DE111 spores and vegetative cells appeared in ileal fluid 3 hours after ingestion, showing spores survived the stomach and germinated in the small intestine. Cited by the BS50 trial authors as evidence that Bacillus spores can germinate in the human gut; BS50 germination itself has not been measured. Four of seven authors were Deerland employees.